Press release
Postpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace
DelveInsight's "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Postpartum Depression Market Report
* July 2024:- Reunion Neuroscience Inc.:- The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
* July 2024:- Gerbera Therapeutics Inc.- A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression. The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
* The total diagnosed prevalent population of Postpartum Depression in the 7 major markets was found to be 1,155,349 in 2020. In case of Postpartum Depression patients in the United States, the diagnosed prevalent cases were found to be 620,944 in 2020, which is expected to increase by 2032.
* In the EU5 countries the diagnosed prevalence of Postpartum Depression was found to be maximum in France with 99,815 cases, followed by the United Kingdom with 99,520 cases in2020. While, the least number of cases were found in Spain, i.e., 57,396 in 2020.
* The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
* Promising Postpartum Depression Therapies such as Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.
Delve deep into the Postpartum Depression Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Postpartum Depression Market Forecast. Click here to shape the future @ Postpartum Depression Prevalence [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Postpartum Depression Overview
Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.
Postpartum Depression Epidemiology Insights
* Total Diagnosed Prevalent Population
* Type-specific Diagnosed Prevalence
Navigate the complexities of the Postpartum Depression Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Postpartum Depression Market Forecast. Click here to get more insights @ Postpartum Depression Treatment Market [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Postpartum Depression Market Insights
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in the treatment of PPD. Other treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary. Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR(Fluvoxamine Maleate) and Paxil CR (paroxetine) form the mainstay drug treatment for PPD. Although these drugs are approved for treating depression related disorders such as major depressive disorder (MDD), obsessive compulsive disorder (OCD), post - traumatic stress disorder (PTSD),treatment-resistant depression (TRD), etc., but they are being used as off-label drugs for the Postpartum Depression treatment.
Postpartum Depression Drug Market
The majorly used current therapeutic classes for treating PPD include Selective serotonin reuptake inhibitors (SSRIs), Serotonin non-epinephrine reuptake inhibitors (SRNIs), Atypical anti-depressants and Anti-psychotics Combination therapies (SSRIs and SRNIs). Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Postpartum Depression. Owing to the positive outcomes of the few products during the developmental stage by key players such as Sage Therapeutics and others, the market is expected to witness a significant positive shift in the Postpartum Depression Market Size
Postpartum Depression Market Dynamics
The dynamics of Postpartum Depression (PPD) market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2024-2034.
Postpartum Depression Drugs Uptake
* Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type A -aminobutyric acid (GABAA ) receptors and a pharmacokinetic profile that is intended for daily oral dosing. The drug is being study in NEST program for PPD, under this one phase III (ROBIN Study; NCT02978326; 30 mg dose) is completed and second study (SKYLARK study; NCT04442503; 50 mg dose) is recruiting. The results from Robin study had shown a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p = 0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up.
* Brii Biosciences is developing BRII-296, a GABAA PAM, for treating PPD. The company started the phase I trial in April 2021 and expects to start phase III trial in H1 2022 and a trial for PPD prevention is under consideration. The topline data readout for Phase I study was expected in 4Q 2021.
* Lipocine's LPCN1154 Is an oral neuron-steroid being developed for the treatment of PPD. The drug is expected to be an "at home" treatment with easier treatment access than the current standard of care invasive option that requires hospitalization with significant limitations. Moreover, LPCN 1154 is expected to provide the required level of privacy for a mother, avoiding bonding/breast feeding interruptions due to the required hospitalizations for the current option. The company has completed a phase I PK study to assess dose proportionality with LPCN 1154 in which dose proportionality was observed and phase II trial is in progress, as per the company's pipeline, as the US FDA had cleared the Investigational New Drug Application to initiate a Phase II study to evaluate the therapeutic potential of LPCN 1154 for the treatment of PPD in adults.
Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Postpartum Depression Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
* Postpartum Depression Therapies- Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.
* Postpartum Depression Market Dynamics: Postpartum Depression Market drivers and Postpartum Depression Market Barriers
* Postpartum Depression Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Postpartum Depression Unmet Needs, KOL's views, Analyst's views, Postpartum Depression Market Access and Reimbursement
Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Postpartum Depression Market Overview at a Glance
4 Executive Summary of Postpartum Depression
5 Key events
6 Disease Background and Overview
7 Treatment and Management
8 Methodology
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Postpartum Depression (PPD): Seven Major Market Analysis
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postpartum-depression-drugs-market-size-report-2034-pfizer-sage-therapeutics-lipocine-inc-eli-lilly-and-company-gsk-canopie-talkspace]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Postpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace here
News-ID: 3607853 • Views: …
More Releases from ABNewswire

Realtor Agent in San Diego, CA Leverages Biotech and University Growth to Serve …
San Diego, CA - A well-known real estate professional is capitalizing on San Diego's thriving biotech sector and university presence to create tailored services for first-time homebuyers entering the market. This strategic focus addresses the unique needs of young professionals and graduates establishing roots in the community.
"San Diego's vibrant ecosystem of research institutions and biotech companies continues to drive substantial employment growth, creating a steady pipeline of well-qualified professionals looking…

What Are Self-Tapping Threaded Inserts? Types, Installation, and Applications
Image: https://ecdn6.globalso.com/upload/p/147/image_other/2025-08/picture-1.jpg
When people are designing lightweight products, or repairing a worn-out thread, a dependable fastening tool can make a big difference. This is where self tapping threaded inserts can come into play. These inserts eliminate the need for pre-tapping and reduce installation time, as they are engineered to cut their own threads.
They help reinforce assemblies, improve durability, and allow for repeated disassembly without degrading the holding strength, by forming secure…

How To Choose Aluminum Profile For Folding Door
Why Aluminum Profiles [https://www.yx-aluminum.com/construction-aluminum-profile/] Matter for Folding Doors
Aluminum profiles form the backbone of folding door, the right aluminum profile ensures smooth operation, proper weight distribution, and long-term performance, while the wrong choice can lead to sagging, difficulty in opening/closing, and premature wear.
Image: https://ecdn6.globalso.com/upload/p/2279/image_other/2025-08/modern-design-interior-aluminum-doors-folding-doors-for-balcony-patio-courtyard-entrance.jpg
Key Factors to Consider When Choosing Aluminum Profiles [https://www.yx-aluminum.com/products/]
Alloy Grade
The alloy grade determines the profile's strength, corrosion resistance, and workability:
6063: Most common for doors - excellent corrosion resistance…

RUITE PUMP Delivers Custom 2-Inch Slurry Pumps to Copper Mine in Kazakhstan
Image: https://www.ruitepumps.com/uploads/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250710091254.jpg
RUITE PUMP, a leading provider of robust and efficient pumping solutions, has successfully completed a custom order for a major copper mining operation in Kazakhstan. The order includes specially engineered 2-inch slurry pumps and a full set of wear parts, all meticulously designed to match the specific and demanding conditions of the client's site.
The pumps, now ready for shipment, were developed following an in-depth analysis of the mine's operational…
More Releases for Postpartum
Key Trend Reshaping the Postpartum Depression Market in 2025: Companies Innovati …
What Are the Projections for the Size and Growth Rate of the Postpartum Depression Market?
The postpartum depression market has witnessed exponential growth in recent years. It will grow from $12.15 billion in 2024 to $16.09 billion in 2025, at a CAGR of 32.4%. The historic growth can be attributed to increased awareness about maternal mental health, research progress, public health initiatives, and a rise in screenings.
The postpartum depression market is…
Postpartum Depression Global Market Report 2024 - Postpartum Depression Market S …
The Business Research Company recently released a comprehensive report on the Global Postpartum Depression Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The postpartum depression market…
Elevate Your Strategy: Insights on Postpartum Depression Market Potential
𝐆𝐫𝐨𝐰𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, a renowned Market research firm, introduces its latest research report on the 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭, providing a detailed guide for businesses seeking growth progression. This report is meticulously crafted to aid in investment decisions, offering crucial insights and encouraging strategic investment discretion for new entrants aiming for seamless Market penetration.
𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐑𝐞𝐩𝐨𝐫𝐭 https://growthmarketreports.com/request-sample/4187
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐏𝐨𝐬𝐭𝐩𝐚𝐫𝐭𝐮𝐦 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭:
The global…
Postpartum Hemorrhage Treatment Market Trends | 2022 | Industry Analysis
The global postpartum hemorrhage treatment market size was valued at USD 802.34 in 2021, growing at a CAGR of 5.3% during the forecast period 2022-28. During the postpartum hemorrhage surgical operation, postpartum hemorrhage therapy devices are essential medical equipment. The severe blood loss that occurs in the initial few hours following childbirth is known as postpartum hemorrhage, and it can even result in the death of the mother. It is…
Demand: Postpartum Hemorrhage Devices Market to Fuel Revenue Growth
The global postpartum hemorrhage devices market is estimated to surpass $1,170.3 million by 2027, exhibiting a CAGR of 5.2% from 2020 to 2027.
The report aims to cater scrupulous analysis of the global postpartum hemorrhage devices market by methodically reviewing different facets of the market such as key segments, market dynamics, regional market circumstances, investment opportunities, and top players operating in the market.
In addition, the report offers insights on the current…
Postpartum Depression Therapeutics Market Therapeutic Survey Reviews, Analysis 2 …
The report titled “Postpartum Depression Therapeutics Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts.
The Postpartum Depression Therapeutics was valued…